From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
Area | Time | Treatment 1 | p* | Treatment 2 | p* | Control | p* |
---|---|---|---|---|---|---|---|
Lumbar1 | A.1.1.1.1.1.5. 0 M | 0.45 ± 0.25 | – | 0.49 ± 0.23 | – | 0.50 ± 0.18 | – |
A.1.1.1.1.1.6. 6 M | 0.50 ± 0.16 | 0.785 | 0.48 ± 0.22 | 0.983 | 0.52 ± 0.27 | 0.962 | |
A.1.1.1.1.1.7. 12 M | 0.54 ± 0.19* | 0.045 | 0.55 ± 0.23 | 0.680 | 0.55 ± 0.28 | 0.785 | |
Lumbar2 | A.1.1.1.1.1.8. 0 M | 0.65 ± 0.17 | – | 0.61 ± 0.12 | – | 0.64 ± 0.16 | – |
A.1.1.1.1.1.9. 6 M | 0.78 ± 0.22* | 0.041 | 0.66 ± 0.13 | 0.582 | 0.64 ± 0.17 | 0.992 | |
A.1.1.1.1.1.10. 12 M | 0.72 ± 0.17* | 0.049 | 0.67 ± 0.14 | 0.460 | 0.63 ± 0.14 | 0.980 | |
A.1.1.1.1.1.11. 0 M | 0.69 ± 0.22 | – | 0.62 ± 0.24 | – | 0.70 ± 0.21 | – | |
Lumbar3 | A.1.1.1.1.1.12. 6 M | 0.72 ± 0.13 | 0.914 | 0.69 ± 0.29 | 0.582 | 0.73 ± 0.16 | 0.914 |
A.1.1.1.1.1.13. 12 M | 0.81 ± 0.17*△ | 0.024 | 0.77 ± 0.25* | 0.019 | 0.64 ± 0.27△ | 0.699 | |
A.1.1.1.1.1.14. 0 M | 0.69 ± 0.18 | – | 0.65 ± 0.18 | – | 0.66 ± 0.16 | – | |
Lumbar4 | A.1.1.1.1.1.15. 6 M | 0.74 ± 0.22 | 0.664 | 0.67 ± 0.15 | 0.929 | 0.65 ± 0.17 | 0.983 |
A.1.1.1.1.1.16. 12 M | 0.90 ± 0.21*△ | 0.011 | 0.68 ± 0.14△ | 0.848 | 0.63 ± 0.14△ | 0.862 | |
A.1.1.1.1.1.17. 0 M | 0.54 ± 0.17 | – | 0.57 ± 0.14 | – | 0.57 ± 0.19 | – | |
Ward area | A.1.1.1.1.1.18. 6 M | 0.66 ± 0.14 | 0.076 | 0.54 ± 0.19 | 0.832 | 0.54 ± 0.14 | 0.848 |
A.1.1.1.1.1.19. 12 M | 0.80 ± 0.17*△ | 0.012 | 0.67 ± 0.17*△ | 0.036 | 0.50 ± 0.16△ | 0.411 | |
Femoral neck | A.1.1.1.1.1.20. 0 M | 0.68 ± 0.13 | – | 0.63 ± 0.14 | – | 0.62 ± 0.20 | – |
A.1.1.1.1.1.21. 6 M | 0.84 ± 0.15* | 0.014 | 0.65 ± 0.17 | 0.926 | 0.65 ± 0.17 | 0.855 | |
A.1.1.1.1.1.22. 12 M | 0.80 ± 0.21*△ | 0.047 | 0.69 ± 0.17* | 0.502 | 0.60 ± 0.17△ | 0.933 |